P46082 AF NFT

Non-toxic nonhemagglutinin type E

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeiduhj2sskklpl4y6t2hkfzsnu25jwkyoy4bymwryakhhzkkugzd5i/metadata.json
IPFS of structure file: 
bafybeih6u7qe56l3nv23vcre6x2ptfukcwnuvmkgxq3mx75al4wu5jyeum/AF-P46082-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x53A7A971DEAEFbFd4AF82cFEeF12CD9621402D37
First NFT owner address (bech32): 
genesis12wn6juw74mal6jhc9nlw7ykdjcs5qtfhu8426j
Current NFT ID #47433 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
47433
Accession (UniProt):
P46082
Name::
Non-toxic nonhemagglutinin type E
Experimental Method:
Predicted structure
Sequence source:
CLOSTRIDIUM BOTULINUM

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT P46082 research and analysis (ICN3D with VR)

FASTA sequences

>sp|P46082|BXEN_CLOBO Non-toxic nonhemagglutinin type E OS=Clostridium botulinum OX=1491 GN=ent-120 PE=3 SV=1 MKINGNLNIDSPVDNKNVAIVRSRNQMFFKAFQVAPNIWIVPERYYGESLKINEDQKFDGGIYDSNFLSTNNEKDDFLQATIKLLQRINNNVVGAKLLSLISTAIPFPYENNTEDYRQTNYLSSKNNEHYYTANLVIFGPGSNIIKNNVIYYKKEYAESGMGTMLEIWFQPFLTHKYDEFYVDPALELIKCLIKSLYYLYGIKPNDNLNIPYRLRNEFNSLEYSELNMIDFLISGGIDYKLLNTNPYWFIDKYFIDTSKNFEKYKNDYEIKIKNNNYIANSIKLYLEQKFKINVKDIWELNLSYFSKEFQIMMPERYNNALNHYYRKEFYVIDYFKNYNINGFKNGQIKTKLPLSKYNKEIINKPELIVNLINQNNTVLMKSNIYGDGLKGTVDNFYSNYIIPYNLNYEHSINYFYLDNVNIEEIEKIPPINDEDIYPYRKNADTFIPVYNITKAKEINTTTPLPVNYLQAQMIDSNDINLSSDFLKVISSKGSLVYSFLNNTMDYLEFIKYDKPIDTDKKYYKWLKAIFRNYSLDITETQEISNQFGDTKIIPWIGRALNILNTNNSFVEEFKNLGPISLINKKENITIPKIKIDEIPSSMLNFSFKDLSENLFNIYCKNNFYLKKIYYNFLDQWWTQYYSQYFDLICMASKSVLAQEKLIKKLIQKQLRYLMENSNISSTNLILINLTTTNTLRDISNQSQIAINNIDKFFNNAAMCVFENNIYPKFTSFMEQCIKNINKSTKEFILKCTNINETEKSHLIMQNSFSNLDFDFLDIQNMKNLFNLYTELLIKEQTSPYELSLYAFQEQDNNVIGDTSGKNTLVEYPKDIGLVYGINNNAIHLTGANQNIKFTNDYFENGLTNNFSIYFWLRNLKQNTIKSKLIGSKEDNCGWEIYFENDGLVFNIIDSNGNEKNIYLSNISNKSWHYIVISINRLKDQLLIFIDNILVANEDIKEILNIYSSDIISLLSDNNNVYIEGLSVLNKTINSNEILTDYFSDLNNSYIRNFDEEILQYNRTYELFNYVFPEIAINKIEQNNNIYLSINNENNLNFKPLKFKLLNTNPNKQYVQKWDEVIFSVLDGTEKYLDISTTNNRIQLVDNKNNAQIFIINNDIFISNCLTLTYNNVNVYLSIKNQDYNWVICDLNHDIPKKSYLWILKNI